Cogent Biosciences Files NDA for Bezuclastinib in GIST, Citing Strong Phase 3 Data and Expedited FDA Review
Summary
Cogent Biosciences has completed the submission of its New Drug Application (NDA) to the FDA for bezuclastinib in patients with gastrointestinal stromal tumors (GIST) who have received prior imatinib treatment. This significant regulatory milestone, which builds on the company's previously reported clinical and regulatory progress, leverages positive Phase 3 PEAK trial results demonstrating a 50% reduction in the risk of disease progression or death. The NDA is being reviewed under the FDA's Real-Time Oncology Review (RTOR) program, following earlier Breakthrough Therapy Designation, suggesting an expedited path to potential approval. This submission is a critical step towards commercialization for Cogent's lead asset, potentially opening a new revenue stream and significantly impacting the company's valuation. Investors will now monitor the FDA's acceptance of the NDA, the setting of a PDUFA date, and the upcoming presentation of full PEAK trial results in the first half of 2026. The company also anticipates another NDA submission for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) in H1 2026.
At the time of this announcement, COGT was trading at $38.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $3.72 to $43.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.